Innate Pharma (NASDAQ:IPHA – Get Free Report) will likely be posting its Q2 2026 results before the market opens on Thursday, September 17th. Analysts expect the company to announce earnings of ($0.2946) per share and revenue of $6.3530 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, September 17, 2026 at 8:00 AM ET.
Innate Pharma Stock Down 1.1%
Innate Pharma stock opened at $1.85 on Tuesday. Innate Pharma has a 12-month low of $1.17 and a 12-month high of $2.71. The firm’s 50-day moving average is $1.97 and its two-hundred day moving average is $1.74.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on IPHA. Citigroup upgraded shares of Innate Pharma from a “buy” rating to an “outperform” rating in a research report on Tuesday, August 11th. HC Wainwright boosted their price target on Innate Pharma from $5.00 to $7.00 and gave the company a “buy” rating in a report on Monday, August 10th. Weiss Ratings raised Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 26th. BTIG Research raised their price objective on Innate Pharma from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, Leerink Partners upgraded Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 price objective on the stock in a report on Tuesday, August 11th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $6.67.
Innate Pharma Company Profile
Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.
The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.
Further Reading
- Five stocks we like better than Innate Pharma
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
